[1] Strunk H, harinova M. Transjugular intrahepatic portosystemic shunt (TIPS): pathophysiologic basics, actual indications and results with review of the literature. Rofo,2018,190:701-711.
[2] de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol,2015,63: 743-752.
[3] Garcia-Tsao G, Abraldes J, Berzigotti A, et al. Portal Hyper-tensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis, and Management: 2016 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology,2017,65: 310-335.
[4] Rössle M, Richter GM, Nöldge G, et al. New non-operative treatment for variceal haemorrhage. Lancet,1989, 2:153. .
[5] Saad WE, Darwish WM, Davies MG, et al.,Stent-grafts for transjugular intrahepatic portosystemic shunt creation: specialized TIPS stent-graft versus generic stent-graft/bare stent combination. J Vasc Interv Radiol,2010,21:1512-1520.
[6] Wang Q, Lv Y, Bai M, et al. Eight millimeter covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding. J Hepatol,2017,67:508-516.
[7] Perry BC, Kwan SW. Portosystemic shunt: stable utilization and improoved outcomes, two decades after the transjugular intrahepatic portosystemic shunt. J Am Coll Radiol,2015,12(12 Pt B):1427-1433.
[8] Miraglia R, Maruzzelli L, Di Piazza A, et al. Transjugular intrahepatic portosystemic shunt using the new gore viatorr controlled expansion endoprosthesis: prospective, single-center, preliminary experience. Cardiovasc Intervent Radiol,2019,42:78-86.
[9] European Association for the Study of the Liver. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the Management of Patients with Decompensated Cirrhosis. J Hepatol, 2018,69:406-460.
[10] Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology,2010,51: 306.
[11] Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology,2004,40:793-801.
[12] Garciía-Pagaá n JC, Caca K, Bureau C, et al. Early Use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med,2010,362:2370-2379.
[13] Njei B, McCarty TR, Laine L. Early transjugular intrahepatic portosystemic shunt in US patients hospitalized with acute esophageal variceal bleeding. J Gastroenterol Hepatol,2017, 32:852-858.
[14] Thabut D, Pauwels A, Carbonell N, et al. Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicenter audit with real-life results. J Hepatol,2017,68:73-81.
[15] Lv Y, Zuo L, Zhu X, et al. Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study. Gut, 2019,68:1297-1310.
[16] Lv Y, Yang Z, Liu L, et al. Early TIPS with covered stent versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomized controlled trial. Lancet Gastroenterol Hepatol,2019,4:587-598.
[17] 中华医学会放射学分会介入学组 经颈静脉肝内门体分流专家共识.中华放射学杂志,2017,51:324-333.
[18] Luo X, Wang Z, Zhou B, et al. Advanced cirrhosis combined with portal vein thrombosis: a randomized controlled trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology,2015,276:286-293.
[19] Sauerbruch T, Mengel M, Dollinger M, et al. Prevention of rebleeding from esophageal varices in patients with cirrhosis receivinv small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology,2015,149:660-668,e1.
[20] Holster IL, Tjwa ET, Moelker A, et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β-block for prevention of varical rebleeding. Hepatology,2016,63:581-589.
[21] Lv Y, Qi X, He C, et al. Covered TIPS versus endoscopic bland ligation plus propranolol for the prevention of varical rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut,2018,67:2156-2168.
[22] Bosch J, Abraldes JG, Berzigotti A. et al. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol,2009,6: 573-582.
[23] Zhang M, Wang G, Zhao L, et al. Second prophylaxis of variceal bleeding in cirrhotic patients with a high HVPG. Scand J Gastroenterol, 2016,51:1502-1506.
[24] Liu J, Shi Q, Xiao S, et al. Using transjugular intrahepatic portosystemic shunt as the first-line therapy in secondary prophylaxis of variceal hemorrhage. J Gastroenterol Hepatol,2019 Jun 20. [Epub ahead of print].
[25] Sharma M, Singh S, Desai V, et al. Comparsion of therapies for primary prevention of esophageal variceal bleeding: a systematic review and network meta-analysis. Hepatology,2019,69:1657-1675.
[26] de Souza AR, La Mural V, Reverter E, et al. Patients whose first episode of bleeding occurs while taking a β-block have high long-term risks of rebleeding and death. Clin Gastroenterol Hepatol,2012,10:670-676.
[27] Albillos A, Zamora J, Martinez J, et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: results of an individual patient meta-analysis. Hepatology,2017,66:1219-1231.
[28] Qi X, Su C, Ren W, et al. Association between portal vein thrombosis and risk of bleeding in lver cirrhosis: a systematic review of the literature. Clin Res Hepatol Gastroenterol,2015, 39:683-691.
[29] Dell’Era A, Lannuzzi F, Fabris FM, et al. Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation. Dig Liver Dis,2014,46:152-156.
[30] Qi XS, Bai M, Fan DM. Nonselective β-blockers may induce development of portal vein thrombosis in cirrhosis. World J Gastroenterol,2014,28,20:11463-11466.
[31] Garciía-Pagaán JC, Barrufet M, Cardenas A, et al. Mana-gement of gastric varices. Clin Gastroenterol Hepatol,2014,12: 919-928,e1.
[32] Tangcheewinsirkul N, Suankratay C. Acute pulmonary embo-lism following endoscopic sclerotherapy for gastroesophageal variceal hemorrhage: a case report and literature review. SAGE Open Med Case Rep,2019,7:2050313X19838946.
[33] Hou MC, Lin HC, Lee HS, et al. A randomized trial of endoscopic cyanoacrylate injection for acute gastric variceal bleeding: 0.5 versus 1.0ml. Gastrointest Endosc,2009,70: 668-675.
[34] Tseng Y, Ma L, Luo T, et al.Patient response to endoscopic therapy for gastroesophageal varices based on endoscopic ultrasound findings. Gut Liver,2018, 12:562-570.
[35] Ma L, Tseng Y, Luo T, et al. Risk stratification for secondary prophylaxis of gastric varices due to portal hypertension. Dig Liver Dis,2019 Jun 12. [Epub ahead of print].
[36] Saad WE, Wagner CC, Lippert A, et al. Protective value of TIPS against the development of hydrothorax/ascites and upper gastrointestinal bleeding after balloon-occluded retrograde transvenous obliteration (BRTO). Am J Gastroenterol,2013,108:1612-1619.
[37] 中国医师协会介入医师分会. 中国门静脉高压经颈静脉肝内门体分流术临床实践指南.中华肝脏病杂志, 2019,27:582-593 |
